Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

The global gene therapy market size was valued at USD 6.30 billion in 2024 and is projected to reach from USD 7.47 billion in ...

An Express License provides fast, simple and affordable access to the CRISPR/Cas9 patent portfolio through a non-exclusive ...

An Express License provides fast, simple and affordable access to the CRISPR/Cas9 patent portfolio through a non-exclusive internal research license. DUBLIN and CHESHIRE, United Kingdom ...

Dr. Petr Chlanda, virologist and research group leader at the Heidelberg Medical Faculty of Heidelberg University, has been awarded more than 720,000 euros in funding from the European Union for his ...

Gene editing involves precise changes in DNA sequences using enzymes, revolutionizing medical, agricultural, and research ...

The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

Genome editing with CRISPR-Cas is often associated with the induction of mutations. However, a team of researchers from the Swiss University of Lausanne now shows that it can also be used to repair ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against the other CRISPR stocks.

In gene and cell therapy, RNP-mediated CRISPR gene editing is quickly emerging as the new norm. For many gene editing firms, GenScript has created hundreds of Cas9, Cas12a, Cas13a, MAD7 ...